Upstream Bio (NASDAQ:UPB) Downgraded by JPMorgan Chase & Co. to Neutral

Upstream Bio (NASDAQ:UPB) was downgraded by equities researchers at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued on Friday, MarketBeat.com reports. They currently have a $8.00 target price on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 25.39% from the company’s current price.

Several other equities research analysts have also recently commented on the stock. Wall Street Zen cut shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Mizuho lowered their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. HC Wainwright assumed coverage on shares of Upstream Bio in a research report on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price target for the company. Evercore cut shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective for the company. in a report on Friday, March 27th. Finally, Weiss Ratings downgraded shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $33.17.

Upstream Bio Price Performance

Shares of NASDAQ:UPB opened at $6.38 on Friday. Upstream Bio has a one year low of $6.11 and a one year high of $33.68. The company has a 50 day moving average of $8.84 and a 200-day moving average of $16.91. The stock has a market cap of $347.20 million, a price-to-earnings ratio of -2.19 and a beta of 1.10.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.02). Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%.The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.03 million. Equities research analysts anticipate that Upstream Bio will post -2.99 earnings per share for the current year.

Institutional Investors Weigh In On Upstream Bio

Several large investors have recently modified their holdings of UPB. GF Fund Management CO. LTD. acquired a new stake in shares of Upstream Bio during the fourth quarter worth about $29,000. Torren Management LLC bought a new stake in Upstream Bio during the 4th quarter worth approximately $30,000. BNP Paribas Financial Markets raised its holdings in Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after buying an additional 2,158 shares during the period. Legal & General Group Plc raised its holdings in Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after buying an additional 1,440 shares during the period. Finally, Empowered Funds LLC bought a new position in Upstream Bio in the fourth quarter valued at approximately $45,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.